CC-115 and enzalutamide reduce the level of PSA in prostate cancer, producing a synergistic effect.CC-115 inhibited the activation of mTORC1/2 and DNA-PK, leading to the death of primary NSCLC cells. Here, PRKDC is linked to prostate carcinoma.